[Clinical evaluation of cefpodoxime proxetil on the treatment of bacterial infections].
122 patients with bacterial infections of respiratory tract, ear, nose, and throat, urinary tract and skin and soft tissue were treated with cefpodoxime proxetil. In the treatments of patients with clinical efficacy tates of cefpodoxime proxetil for infections in these four systems were 90.0%, 97.5%, 90.0% and 86.4%, respectively. The bacterial clearance rate of gram-positive bacterial was 96.9%, and that of gram-negative bacteria 96.4%. Adverse drug reaction rate was 18.9%.
Li
J T
JT
Institute of Clinical Pharmacology, Beijing Medical University.
Hou
J
J
Kao
L
L
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D015296:Ceftizoxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011355:Prodrugs / Q000009:adverse effects / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy; D000097627:Cefpodoxime Proxetil
D015296:Ceftizoxime; D011355:Prodrugs; D000097627:Cefpodoxime Proxetil